基于醛酮还原酶1C3的抗肿瘤药物研究进展  

Advances in Research on Antitumor Drugs Based on Aldo-keto Reductase 1C3

作　　者：卢兆强 段建新 孟繁英 李安蓉 LU Zhaoqiang;DUAN Jianxin;MENG Fanying;LI Anrong(Ascentawits Pharmaceuticals,Ltd,Shenzhen 518118.China)

机构地区：[1]深圳艾欣达伟医药科技有限公司,广东深圳518118

出　　处：《药学进展》2023年第3期164-178,共15页Progress in Pharmaceutical Sciences

摘　　要：醛酮还原酶(aldo-keto reductase,AKR)1C3是AKR超家族的成员之一,在多种恶性实体瘤和血液肿瘤细胞中的表达水平高于正常细胞,并与癌症的发生和发展以及肿瘤对化疗/免疫疗法的耐药性和对放疗的抵抗性密切相关。研究已证明,AKR1C3既可以作为生物标志物,用于肿瘤病人筛选、指导用药和预后诊断,也可作为抗肿瘤药物的新靶标,用于药物设计和研发。基于AKR1C3的抗肿瘤药物有望为临床用药提供新的解决方案。回顾了近年来基于AKR1C3的抗肿瘤药物的研究进展,并对该研究领域进行了展望。Aldo-keto reductase(AKR)1C3 is a member of the AKR superfamily.Its expression level in a variety of malignant solid tumor cells and hematologic tumor cells is higher than that in normal cells,which is closely related to the occurrence and development of cancer,as well as tumor resistance to chemotherapy/immunotherapy and resistance to radiotherapy.Studies have proved that AKRIC3 can be used both as a biomarker for screening,drug guidance and prognostic diagnosis of tumor patients,and as a new target of anti-tumor drugs for drug design and development.Anti-tumor drugs based on AKRIC3 are expected to provide novel solutions for clinical use.In this article,the research progress of anti-tumor drugs based on AKRIC3 in rcent years has been reviewed,and an outlook of the research field has been provided.

关 键 词：醛酮还原酶1C3 生物标志物 靶向抗肿瘤药物 前药 活化 

分 类 号：R914.2[医药卫生—药物化学]